These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 10717328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H, Billiart I, Chabrun V, Chieze S, Lemerre D, Germain T, Ferrand V, Meurice JC, Daban A, Tourani JM.
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [Abstract] [Full Text] [Related]

  • 5. Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Chen YM, Perng RP, Whang-Peng J, Wu HW, Lin WC, Tsai CM.
    Lung Cancer; 2000 Dec; 30(3):199-202. PubMed ID: 11137205
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
    Chen Y, Perng RP, Yang KY, Lin WC, Wu HW, Tsai CM, Whang-Peng J.
    Lung Cancer; 2000 Aug; 29(2):139-46. PubMed ID: 10963844
    [Abstract] [Full Text] [Related]

  • 8. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP.
    Int J Cancer; 2002 Mar 01; 98(1):141-7. PubMed ID: 11857398
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S, Gebbia N.
    Br J Cancer; 1997 Mar 01; 76(11):1509-17. PubMed ID: 9400950
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
    Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ.
    Cancer; 2000 Aug 15; 89(4):774-82. PubMed ID: 10951340
    [Abstract] [Full Text] [Related]

  • 11. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V, Efremidis A, Berchier MC, Collon T, Meert AP, Scherpereel A, Ninane V, Paesmans M, Berghmans T, European Lung Cancer Working Party.
    Ann Oncol; 2007 Jun 15; 18(6):1037-42. PubMed ID: 17404152
    [Abstract] [Full Text] [Related]

  • 12. Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
    Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C.
    Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S25-8. PubMed ID: 12042986
    [Abstract] [Full Text] [Related]

  • 13. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY, Kim WS, Kim K, Jung CW, Im YH, Kim HJ, Kang WK, Lee HG, Kwon OJ, Rhee CH, Park CH, Park K.
    Jpn J Clin Oncol; 2003 Oct 15; 33(10):509-13. PubMed ID: 14623918
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
    Scinto AF, Ferraresi V, Milella M, Tucci E, Santomaggio C, Pasquali-Lasagni R, Del Vecchio MR, Campioni N, Nardi M, Cognetti F.
    Br J Cancer; 1999 Nov 15; 81(6):1031-6. PubMed ID: 10576661
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Vansteenkiste J, Vandebroek J, Mariën S, Roex L, Bertrand P, Bockaert J, De Beukelaar T, Deman R, De Muynck P, Ulrichts H.
    Lung Cancer; 1995 Dec 15; 13(3):295-303. PubMed ID: 8719069
    [Abstract] [Full Text] [Related]

  • 19. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
    Ahn JB, Ko WK, Lee JG, Shim KY, Jeung HC, Park JO, Yoo NC, Kim BS, Kim SK, Kim SK, Kim JH.
    Am J Clin Oncol; 2000 Dec 15; 23(6):622-8. PubMed ID: 11202811
    [Abstract] [Full Text] [Related]

  • 20. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators.
    Lancet Oncol; 2015 Jul 15; 16(7):763-74. PubMed ID: 26045340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.